The following features would enhance the value of an obesity therapeutic, but would likely be assessed in follow-up trials or even post-approval: Additional efficacy in obesity-related co-morbidities
Our analysis indicates that between 20 and 30 percent of annual patients stop using the drugs, particularly those focused on weight loss, and these patients regain about two-thirds of the weight they lost
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
The semaglutide absorbs directly through the sublingual mucosa into the capillary bed beneath the tongue, bypassing the digestive system entirely
Protein sources can be both animal-based and plant-based
Keep taking your probiotic to keep those benefits going